European journal of nuclear medicine and molecular imaging · 2025
Head-to-head comparison of 68Ga-FT-FAPI with 68Ga-FAPI-04 in patients with gastrointestinal tumors.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Wenhui, Yang Shu, Ye Jiajun, Quan Zhiyong, Zhang Mingru, Li Guiyu, Zhu Zifan, Wang Jia, Ma Taoqi, Wang Junling, Liu Yu, Liu Zhibo, Kang Fei, Wang Jing
Аннотация
PURPOSE: FT-FAPI (FT, fast treatment) is a new FAP inhibitor with the potential to be used as a drug in boron neutron capture therapy (BNCT). The aim of this prospective study was to compare the diagnostic performance of 68Ga-FT-FAPI and 68Ga-FAPI-04 in patients with gastrointestinal (GI) tumors.
METHODS: The study enrolled patients with histologically confirmed GI tumors diagnosed between March 2024 to April 2025 in Xijing Hospital. All the patients underwent paired 68Ga-FT-FAPI PET/CT and 68Ga-FAPI-04 PET/CT scans within three days. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), and retention index (RI) of the primary tumor and metastatic lesions were analyzed for both imaging modalities.
RESULTS: A total of 19 patients with GI tumors (12 males and 7 females) with a median age of 61.3 years (range, 40-75 years) were finally enrolled in this study. A total of 186 lesions were identified.68Ga-FT-FAPI identified all the tumors clearly with a higher uptake than 68Ga-FAPI-04 (13.3 vs. 10.0, P < 0.001), and better TBR (13.8 vs. 8.2, P < 0.001). In terms of retention, the RIs of 68Ga-FT-FAPI were significantly higher than those of 68Ga-FAPI-04 for detecting lymph node metastases (88.7% vs. 76.2%, P = 0.001, n = 62), liver metastases (115.4% vs. 101.5%, P = 0.032, n = 38), bone metastases (70.8% vs. 57.0%, P = 0.008, n = 24), and peritoneal metastases (102.9% vs. 87.0%, P = 0.041, n = 26).
CONCLUSION: 68Ga-FT-FAPI had a superior performance than 68Ga-FAPI-04 for uptake in lesions and a higher detection rate, especially for identifying metastases in lymph nodes, bone, liver and peritoneum. 68Ga-FT-FAPI may therefore be an effective BNCT agent for diagnosis and treatment of GI tumors.
METHODS: The study enrolled patients with histologically confirmed GI tumors diagnosed between March 2024 to April 2025 in Xijing Hospital. All the patients underwent paired 68Ga-FT-FAPI PET/CT and 68Ga-FAPI-04 PET/CT scans within three days. The maximum standard uptake value (SUVmax), tumor-to-background ratio (TBR), and retention index (RI) of the primary tumor and metastatic lesions were analyzed for both imaging modalities.
RESULTS: A total of 19 patients with GI tumors (12 males and 7 females) with a median age of 61.3 years (range, 40-75 years) were finally enrolled in this study. A total of 186 lesions were identified.68Ga-FT-FAPI identified all the tumors clearly with a higher uptake than 68Ga-FAPI-04 (13.3 vs. 10.0, P < 0.001), and better TBR (13.8 vs. 8.2, P < 0.001). In terms of retention, the RIs of 68Ga-FT-FAPI were significantly higher than those of 68Ga-FAPI-04 for detecting lymph node metastases (88.7% vs. 76.2%, P = 0.001, n = 62), liver metastases (115.4% vs. 101.5%, P = 0.032, n = 38), bone metastases (70.8% vs. 57.0%, P = 0.008, n = 24), and peritoneal metastases (102.9% vs. 87.0%, P = 0.041, n = 26).
CONCLUSION: 68Ga-FT-FAPI had a superior performance than 68Ga-FAPI-04 for uptake in lesions and a higher detection rate, especially for identifying metastases in lymph nodes, bone, liver and peritoneum. 68Ga-FT-FAPI may therefore be an effective BNCT agent for diagnosis and treatment of GI tumors.